β-Amyloid precursor protein, ETS-2 and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21, are not overexpressed in fetal Down syndrome: further evidence against gene dosage effect
Down syndrome (DS) is the most common human chromosomal abnormality caused by an extra copy of chromosome 21 and characterized clinically by somatic anomalies, mental retardation and precocious dementia. The phenotype of DS is thought to result from overexpression of a gene or genes located on the triplicated chromosome or chromosome region. Reports that challenge this notion, however, have been published. To add to this body of evidence, the expression of β-amyloid precursor protein (APP), ETS-2 and collagen α1 (VI) chain precursor, encoded on chromosome 21, was investigated in fetal brain by western blot and two-dimensional electrophoresis (2-DE). Western blot detected APP and ETS-2 that migrated at -75 and 50kDa, respectively. Subsequent densitometric analysis of APP and ETS-2 immuno-reactivity did not produce any significant change between controls and DS. Since the metabolic fate of APP determines the propensity of amyloid β production, the expression of the secreted forms of APP (sAPP) had been examined. Neither the expression of sAPPaα nor sAPPß showed any detectable changes among the two groups. Collagen α1(VI) chain precursor, a protein resolved as a single spot on 2D gel was identified by matrix associated laser desorption ionization mass spectroscopy. Quantitative analysis of this spot using the 2D Image Master software revealed a significant decrease in fetal DS (P < 0.01) compared to controls. Linear regression analysis did not show any correlation between protein levels and age. The current data suggest that overexpression per se can not fully explain the DS phenotype.
KeywordsDown Syndrome Amyloid Precursor Protein Gene Dosage Effect Down Syndrome Patient Amyloid Precursor Protein Gene
Unable to display preview. Download preview PDF.
- Epstein CJ (1995) Down Syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 7th edn, vol. I. McGraw Hill,New York, pp 749–794Google Scholar
- Greber-Platzer S, Schatzmann-Turhani D, Wollenek G, Lubec G (1998) Evidence against the current hypothesis of “gene dosage effects” of trisomy 21: ETS-2, encoded on chromosome 21 is not overexpressed in hearts of patients with Down syndrome.Biochem Biophys Res Commun 254: 395–399CrossRefGoogle Scholar
- Greber-Platzer S, Schatzmann-Turhani D, Cairns D, Balcz B, Lubec G (1999) Expression of the transcription factor ETS-2 in brain of patients with Down syndrome-evidence against the overexpression gene hypothesis. J Neural Transm [Suppl] 57: 269–281Google Scholar
- Howlett DR, James S, Allsop D, Roberts GW (1995) The biology and molecular pathology of β.amyloid protein. In: Dawbarn D, Allen SJ (eds) Neurobiology of Alzheimer’s disease. BIOS Scientific Publishers, Oxford, pp 9–49Google Scholar
- Levine JM, Nishiyama A (1996) The NG-2 chondrotin sulfate proteoglycan: a multi functional proteoglycan associated with immature cells. Perspect Dev Biol 3: 545–559Google Scholar
- Maraoulakou IG, Papas TS, Green JE (1994) Differential expression of ETS-1 and ETS-2 genes during murine embriogenesis. Oncogene 9: 1551–1565Google Scholar
- Pritchard MA, Kola I (1999) The “gene dosage effect” versus the “amplified developmental instability” hypothesis in Down syndrome. J Neural Transm [Suppl] 57: 293–303Google Scholar
- Shapiro BL (1999) The Down syndrome critical region. J Neural Transm [Suppl] 57: 41–60Google Scholar
- Wasco W, Tanzi RE (1995) Molecular genetics of amyloid and apolipoprotein E in Alzheimer’s disease. In: Dawbarn D, Allen SJ (eds) Neurobiology of Alzheimer’s disease. BIOS Scientific Publishers, Oxford, pp 51–76Google Scholar